Latest Content

In this week's Pharma Pulse, Trump nominates Heidi Overton to lead the FDA, EVERSANA expands its AI-powered commercialization platform into medical affairs and market research, Moderna and Merck's personalized mRNA cancer vaccine clears a landmark Phase 3 trial, and IAG Cargo expands its pharma cold chain network into Kuala Lumpur.

Cardinal Health's Michelle Britt discusses the operating costs, cash flow strain and reimbursement pressures facing independent pharmacies, and how owners are diversifying revenue to stay open.

AI-enabled pharmacovigilance is becoming a commercial capability that protects product value and speeds evidence-based market access decisions.

Trump is expected to pick White House aide Dr. Heidi Overton to lead the FDA, pending Senate confirmation, as the agency works to rebuild industry trust.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.

EVERSANA's Vikram Anand breaks down FDA data on complete response letters, showing how gaps in pharmacovigilance and safety readiness, not manufacturing alone, drive costly delays in drug commercialization.

Separating the combination MMR shot into three vaccines would not just change how children are immunized. It would require building three new supply chains from a licensing base that does not yet exist.

Episode 2 of Supply Chain Signal breaks down the July 31 and September 29 Section 232 deadlines and the proposed generics tariff plan, and what they mean for reshoring.

DSCSA verifies package movement, but resilience requires visibility into capacity, quality and sourcing risk.

In this week's Pharma Pulse, Eli Lilly sues companies over black-market retatrutide sales, Bristol Myers Squibb commits $2.3 billion to a new Houston manufacturing campus, and FDA opens an assessment of small dispensers' DSCSA tracing capabilities.

Ed Schoonveld examines how AI is reshaping drug pricing and access, from payer decisions to prescribing, and what it means for new drug treatments.

Across pricing, supply chain, and patient support, the playbooks of pharma commercialization are being rewritten at once for a new era.

Adam Colborn explains why affordability and access aren't the same thing for TrumpRx, and how pharmacy participation gaps can leave patients stuck.